Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China

Yafei Shi, Wei Chen, Yujun Zhang, Mingming Bo, Chunyu Li, Mingyu Zhang, Guohui Li